



TREATING *Schizophrenia:* CAN WE DO BETTER?

INDUSTRY SATELLITE SYMPOSIUM ON THE OCCASION OF THE 34TH ECNP CONGRESS

WITH EDUCATIONAL FINANCIAL SUPPORT PROVIDED BY GLOBAL MEDICAL EDUCATION,
A CLINICAL CARE OPTIONS COMPANY, AND SUNOVION

Saturday, 02 October 2021

14:00 - 15:30

**Centro de Congressos de Lisboa
Pavilion 3**

Lisbon, Portugal

Despite pharmacologic advances, schizophrenia remains a severe mental health disorder and leading cause of disability and premature mortality worldwide. This symposium aims to summarize clinical targets and unmet needs within a neurobiologic framework to which novel and emerging pharmacologic agents are mapped. Doing so, the speakers will provide a cutting-edge update on the latest developments in the pharmacologic treatment of schizophrenia informed by advances in understanding of the neurobiology underlying the disorder and its dimensional components.

Agenda

14:00 - 14:05: Opening Remarks
– Silvana Galderisi, MD, Chair (Italy)

14:05 - 14:35: Unmet Needs and Novel Receptor Treatment Targets in Schizophrenia
– Oliver Howes, MD (United Kingdom)

14:35 - 15:05: Innovations in Treating Schizophrenia
– Carmen Moreno, MD (Spain)

15:05 - 15:25: Question and Answer Session

15:25 - 15:30: Closing Remarks



The European Accreditation Committee in CNS (EACIC) has granted 2 CME credits to this Industry Satellite Symposium

Both in-person and online participants can claim CME credits via the online congress platform



Deadline: 13 January 2022

www.ecnp.eu/Congress2021/ECNPcongress



GLOBAL MEDICAL
EDUCATION

A CLINICAL CARE OPTIONS COMPANY



CLINICAL CARE OPTIONS®